Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood
Status: | Recruiting |
---|---|
Conditions: | Other Indications, Women's Studies |
Therapuetic Areas: | Other, Reproductive |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/15/2019 |
Start Date: | November 2012 |
End Date: | November 2019 |
Contact: | Melissa Egbert |
Email: | research@natera.com |
Phone: | 650-249-9090 |
Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood
The purpose of this study is to collect maternal blood samples from pregnant women carrying a
fetus with a confirmed diagnosis of chromosomal abnormality or genetic disorder including
microdeletions in order to further develop a non-invasive prenatal screening test based on
fetal DNA isolated from maternal blood.
fetus with a confirmed diagnosis of chromosomal abnormality or genetic disorder including
microdeletions in order to further develop a non-invasive prenatal screening test based on
fetal DNA isolated from maternal blood.
The goal of this study is to further develop a non-invasive prenatal blood test that can
diagnose genetic disorders in the fetus by looking at fetal DNA (genetic material) found in
the mother's bloodstream during pregnancy.
Women carrying a fetus diagnosed with microdeletions/microduplications (small missing or
extra pieces of DNA that can cause problems), aneuploidy (trisomy 21, 18, or 13) or other
genetic disorders will be asked to participate.
If this study is successful, it will reduce the need for invasive procedures during pregnancy
such as amniocentesis and chorionic villus sampling (CVS) but still enable women to find out
accurate information regarding their baby's health early in the pregnancy.
diagnose genetic disorders in the fetus by looking at fetal DNA (genetic material) found in
the mother's bloodstream during pregnancy.
Women carrying a fetus diagnosed with microdeletions/microduplications (small missing or
extra pieces of DNA that can cause problems), aneuploidy (trisomy 21, 18, or 13) or other
genetic disorders will be asked to participate.
If this study is successful, it will reduce the need for invasive procedures during pregnancy
such as amniocentesis and chorionic villus sampling (CVS) but still enable women to find out
accurate information regarding their baby's health early in the pregnancy.
Inclusion Criteria:
- Age 18 or older at enrollment
- Singleton pregnancy
- Fetus with confirmed diagnosis of chromosomal abnormality or genetic disorder through
karyotype, FISH or positive microarray results after amniocentesis or chorionic villus
testing
- The biological father of the fetus at least 18 years of age
- Able to provide informed consent
Exclusion Criteria:
- Women carrying multiples
- Pregnancy is a result of IVF with pre-implantation genetic diagnosis
- Surrogate/egg or sperm donor used
- Previous participation in this study during a previous pregnancy
We found this trial at
5
sites
116th St and Broadway
New York, New York 10027
New York, New York 10027
(212) 854-1754
Principal Investigator: Ronald Wapner, MD
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
Click here to add this to my saved trials
254 Easton Ave
New Brunswick, New Jersey 08901
New Brunswick, New Jersey 08901
(732) 745-8600
Principal Investigator: Angela Ranzini, MD
Phone: 732-339-7602
Saint Peter's University Hospital Located in New Brunswick, NJ, Saint Peter's University Hospital has been...
Click here to add this to my saved trials
San Carlos, California 94070
Principal Investigator: Kim Martin, MD
Phone: 650-249-9090
Click here to add this to my saved trials
San Gabriel, California 91776
Principal Investigator: Ardeshir Karimi, MD
Phone: 626-282-9250
Click here to add this to my saved trials
Washington, District of Columbia 20010
Principal Investigator: Peggy Ye, MD
Click here to add this to my saved trials